Stockreport

Boundless Bio Starts $100 Million U.S. IPO Plan [Seeking Alpha]

Fate Therapeutics, Inc.  (FATE) 
Last fate therapeutics, inc. earnings: 3/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.fatetherapeutics.com/investor-relations
PDF The firm's lead candidate, BBI-355, is in Phase 1 trials for the treatment of oncogene amplified cancers. The global market for solid tumor cancer treatments is forec [Read more]